Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000012018
- Lead Sponsor
- Mie University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) Past history of severe hypersensitivity. 2) History of eribulin use during 6 months prior to consent. 3) Active multiple primary malignancy. 4) Patients with uncontrolled infection. 5) Patient with disease requiring emergent intervention. 6) Patients with progressive brain metastasis requiring treatment during 6 months prior to consent. 7) Patients with severe complications. 8) Pregnant or breastfeeding. 9) Patients who deny contraception during this study. 10) Any other cases that the attending doctor judges not appropriate to enroll to this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method